2025年05月23日 星期五 首页   |   期刊介绍   |   编 委 会   |   投稿指南   |   期刊订阅   |   广告合作   |   联系我们   |   ENGLISH
哈尔滨医药  2025, Vol. 45 Issue (1): 17-20    DOI: 10.3969/j.issn.1001-8131.2025.01.006
  论著 本期目录 | 过刊浏览 | 高级检索 |
免疫组化指标结合肿瘤坏死因子-α、miRNA-107在胃癌疾病诊断中的临床意义
潘治宇1, 高龙潭2, 王宁3
1.新郑市公立人民医院病理科,河南 新郑 451100;
2.河南天佑中西医结合肿瘤医院普外科,河南 新郑 451100;
3.郑州大学附属郑州中心医院病理科,河南 郑州 450000
Immunohistochemical Markers Combined with Tumor Necrosis Factor α The Clinical Significance of miRNA-107 in the Diagnosis of Gastric Cancer
Pan Zhiyu1, Gao Longtan2, Wang Ning3
1. Pathology Department of Xinzheng Public People's Hospital,Xinzheng 451100,Henan;
2. Department of General Surgery,Henan Tianyou Integrated Traditional Chinese and Western Medicine Cancer Hospital,Xinzheng 451100,Henan;
3. Department of Pathology,Zhengzhou Central Hospital Affiliated to Zhengzhou University,Zhengzhou,Henan 450000,China
全文: PDF (630 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 分析免疫组化指标结合肿瘤坏死因子-α、miRNA-107在胃癌疾病诊断中的临床价值。方法 纳入医院收治的胃癌患者(胃癌组)48例,另选择同期到院就诊的良性胃病患者(良性胃癌组)48例、健康体检者(健康组)48名,对所有受检对象进行免疫组化指标检验、肿瘤坏死因子-α以及miRNA-107检验。之后根据胃癌患者的疾病进展程度,将胃癌组患者分为早期组(n=22)、进展期组(n=26),对比两组患者免疫组化指标检验、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)以及miRNA-107检验,以受试者特征曲线(receiver operating characteristic,ROC)分析免疫组化指标检验、肿瘤坏死因子-α以及miRNA-107检验在胃癌疾病中的诊断价值。结果 胃癌组患者其人表皮生长因子受-2(Her-2)、TNF-α、miRNA-107高于其他两组(P<0.05)。与早期组相比,进展期组患者的Her-2、TNF-α以及miRNA-107水平更高,差异有统计学意义(P<0.05)。联合检测在胃癌诊断、良恶性鉴别诊断以及胃癌进展程度的评估中诊断价值最高,其ROC曲线下面积(area under curve,AUC)分别为0.949、0.997以及1.000。结论 Her-2、TNF-α以及miRNA-107水平的上升与胃癌疾病的严重程度之间密切相关,该指标联合检测对明确胃癌诊断、明确胃癌良恶性以及疾病进展程度均具有重要意义。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
潘治宇
高龙潭
王宁
关键词 胃癌免疫组化指标肿瘤坏死因子-α诊断价值    
AbstractObjective To analyze the combination of immunohistochemistry indicators and tumor necrosis factor α、 The clinical value of miRNA-107 in the diagnosis of gastric cancer. Method 48 gastric cancer patients(gastric cancer group)admitted to the hospital were included in the study.In addition,48 benign gastric cancer patients(benign gastric cancer group)and 48 healthy individuals(healthy group)who visited the hospital during the same period were selected.Immunohistochemical indicators and tumor necrosis factor tests were performed on all tested subjects- α And miRNA-107 testing.Subsequently,based on the degree of disease progression of gastric cancer patients,the gastric cancer group was divided into an early group(n=22)and an advanced group(n=26).The immunohistochemical index test and tumor necrosis factor were compared between the two groups of patients- α Tumor crossing factor- α,TNF- α)And miRNA-107 test,receiver operating characteristic(ROC)analysis of immunohistochemical indicators,tumor necrosis factor- α And the diagnostic value of miRNA-107 test in gastric cancer disease. Result In the gastric cancer group,the human epidermal growth factor was regulated by -2(Her-2)and TNF- α、 MiRNA-107 was higher than the other two groups(P<0.05).Compared with the early group,Her-2 and TNF in patients in the advanced group- α And miRNA-107 levels were higher,with significant differences(P<0.05).Joint testing has the highest diagnostic value in the diagnosis,differential diagnosis of benign and malignant gastric cancer,and evaluation of gastric cancer progression.Its Area Under Curve(AUC)values are 0.949,0.997,and 1.000,respectively. Conclusion Her-2,TNF- α The increase in miRNA-107 levels is closely related to the severity of gastric cancer,and the combined detection of this indicator is of great significance in clarifying the diagnosis,malignancy,and progression of gastric cancer.
Key wordsGastric cancer    Immunohistochemical indicators    Tumor necrosis factor- α    Diagnostic value
收稿日期: 2025-02-12     
PACS:  R735.2  
引用本文:   
潘治宇, 高龙潭, 王宁. 免疫组化指标结合肿瘤坏死因子-α、miRNA-107在胃癌疾病诊断中的临床意义[J]. 哈尔滨医药, 2025, 45(1): 17-20.
Pan Zhiyu, Gao Longtan, Wang Ning. Immunohistochemical Markers Combined with Tumor Necrosis Factor α The Clinical Significance of miRNA-107 in the Diagnosis of Gastric Cancer. journal1, 2025, 45(1): 17-20.
链接本文:  
http://www.hrbyybjb.org.cn/CN/10.3969/j.issn.1001-8131.2025.01.006     或     http://www.hrbyybjb.org.cn/CN/Y2025/V45/I1/17
版权所有 © 《哈尔滨医药》编辑部  备案号: 黑ICP备19005758号-1
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn